Ocular hypotensive effect of sublingual administration of timolol

Quaranta, Luciano; Pasquini, Luisa; Cassamali, M.; Hauranieh, N.; Gandolfo, E.; Quaranta, C. A.

doi:10.1007/bf00212945

Cited by 1 publication

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Latanoprost-containing eye drops to be applied daily are the most popular IOP-reducing treatment for patients with ocular hypertension or glaucoma [ 20 ], but poor patient compliance is the main disadvantage of this type of drug formulation. A system for the sustained topical delivery of the PGF2α ester drug bimatoprost from biodegradable polymer inserted intracamerally has recently entered the clinical development phase [ 21 ], being recognized as a potentially favorable alternative to eye drops applied every day.…”

Section: Discussionmentioning

confidence: 99%

“…However, in the case of timolol, another drug routinely applied in the form of eye drops to decrease IOP, administration to one eye of healthy volunteers was associated with a decrease of IOP in both eyes recorded 1 h and 2 h later [13]. Further, two independent groups have reported that, in patients suffering from ocular hypertension, sublingual application of the drug was as effective in decreasing IOP over the subsequent 2 h [14] and 8 h [15] as topical treatment. Latanoprost/timolol fixed-combination eye drops, a combination that is distinctly more active than each drug alone, has recently become commercially available [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Peripheral Latanoprost Administration Lowers Intraocular Pressure in the Wistar Rat

et al. 2020

View full text Add to dashboard Cite

Purpose: Instillation of latanoprost eye drops into the conjunctival sac to lower intraocular pressure (IOP) is the most frequently used treatment for primary open-angle glaucoma. The aim of this study was to evaluate the influence of latanoprost on IOP in the rat when applied peripherally. Methods: A rodent-dedicated tonometer was used to measure IOP in conscious adult male normotensive Wistar rats habituated to the measurement procedure. Commercially available 0.005% latanoprost solutions were continuously delivered to the periphery of the eye over 7 days using mini-pumps inserted subcutaneously in the animal's back, and IOP was measured daily. For comparison, a solution containing an equimolar concentration of latanoprost acid, an active compound of latanoprost, was similarly infused into the eyes of different Wistar rats. Results: Continuous subcutaneous infusion of latanoprost gradually decreased the IOP; the stable nadir of IOP, which was 20% lower than that prior to the start of infusion, was reached on day 3. The effect was statistically significant and fully reversed 2 days after cessation of drug delivery. Continuous subcutaneous application of the solution containing an equimolar amount of latanoprost acid did not appreciably influence the IOP. Conclusion: Subcutaneous continuous delivery of latanoprost decreased the IOP in the conscious normotensive Wistar rats in this study. If this effect is confirmed in humans, it may open the possibility of using peripheral systems of drug delivery, which could significantly improve patient compliance.

show abstract

Section: Discussionmentioning

confidence: 99%